Citations

Clear

9383 citation(s) found for "Thomas, PS".

Abstract PO1-19-02: A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer: NRG-BR007
White, Julia, Mamounas, Eleftherios P. , Théberge, Valérie, Zellars, Richard C. , Shumway, Dean A. , Chen, Guang‐Pei , Julian, Thomas B. , Cecchini, Reena S. , Harris, Eleanor E R , Mamounas, Eleftherios P. , Stover, Daniel G. , Ganz, Patricia A. , Jagsi, Reshma , Anderson, Stewart , Bergom, Carmen , El-Tamer, Mahmoud Bahij , Wolmark, Norman

Mayo Clinic

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: PO1-19-02-PO1-19-02

10.1158/1538-7445.sabcs23-po1-19-02 Get It

Abstract Background: Approximately 50% of newly diagnosed invasive breast cancers are stage 1, with the majority being ER/PR-positive, HER2-negative. Genomic assays such as the Oncotype DX® have identified patients (pts) with reduced risk of distant metastasis and without benefit from chemotherapy added to endocrine therapy, freeing them from excess toxicity. Genomic assays are also recognized as prognostic for in-breast recurrence (IBR) after BCS and could similarly allow de-escalation of adjuvant radiotherapy (RT). Reducing overtreatment is of interest to pts, providers, and payers. Methods: We hypothesize that BCS alone is non-inferior to BCS plus RT for in-breast recurrence and breast preservation in women intending endocrine therapy (ET) for stage 1 invasive breast cancer (ER &/or PR positive, HER2-negative with an Oncotype DX Recurrence Score [RS] of ≤18). Stratification is by age (< 60; ≥60), tumor size (≤1 cm; >1-2cm), and RS (< 11, 11-18). Pts are randomized post-BCS to Arm 1 with breast RT using standard methods (hypo- or conventional-fractionated whole breast RT with/without boost, or APBI) with ≥5 yrs of ET (tamoxifen or AI) or Arm 2 with ≥5 yrs of ET (tamoxifen or AI) alone. The specific regimen of ET in both arms is at the treating physician’s discretion. Eligible pts are stage 1: pT1 (≤2 cm), pN0, age ≥50 to < 70 yrs, s/p BCS with negative margins (no ink on tumor), s/p axillary nodal staging (SNB or ALND), ER &/or PR positive (ASCO/CAP), HER2-negative (ASCO/CAP), and Oncotype DX RS of ≤18 (diagnostic core biopsy or resected specimen). Primary endpoint is in-breast recurrence (invasive breast cancer or DCIS). Secondary endpoints are breast conservation rate, invasive in-breast recurrence, relapse-free interval, distant disease-free survival, overall survival, patient-reported breast pain, patient-reported worry about recurrence, and adherence to ET. We assume a clinically acceptable difference in IBR of 4% at 10 yrs to judge omission of RT as non-inferior (10-yr event-free survival for RT group is 95.6% vs 91.6% for the omission of RT group). BR007 is powered to detect non-inferiority with 80% power and a one-sided α=0.025, assuming that there would be a ramp-up in accrual in the first two years (leveling off in Yrs 3-5); 1,670 pts (835 per arm) are required for randomization. Conservative loss to follow-up is 1% per yr. Some of the T1a pts screened may have Oncotype DX scores >18, making them ineligible for the study. In the accrual process, 1,714 pts will be required to register to ensure that our final randomized cohort is 1,670 pts. Current accrual (07-07-2023) is 555 screened and 488 randomized (~96% of predicted accrual). Support: U10CA180868, -180822, UG1CA189867, UG1CA189867; Susan G. Komen Foundation (JRW). NCT: 04852887. Citation Format: Julia White, Reena Cecchini, Eleanor Harris, Eleftherios Mamounas, Daniel Stover, Patricia Ganz, Reshma Jagsi, Stewart Anderson, Carmen Bergom, Valérie Théberge, Mahmoud El-Tamer, Richard Zellars, Dean Shumway, Guang-Pei Chen, Thomas Julian, Norman Wolmark. A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer: NRG-BR007 [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-19-02.
Abstract GS02-07: Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304
Mamounas, Eleftherios P. , Bandos, Hanna , White, Julia, Julian, Thomas B. , Torres, Mylin A. , Vicini, Frank A. , McCloskey, Susan A. , Gupta, Nilendu , Abu-Rustum, Nadeem, Gandhi, Saumil , Tendulkar, Rahul D. , Fujiwara, Keiichi , Seaward, Samantha A. , Irvin, William , Mutter, Robert W. , Boileau, Jean-François , Muskovitz, Andrew A., Weiss, Anna , Walter, Curran, Seaward, Samantha A , Mamounas, Eleftherios P. , Khan, Atif J. , Shaitelman, Simona Flora , Ganz, Patricia A. , Li, X. Allen , Lucas, Peter C. , Abu‐Rustum, Nadeem R. , Coleman, Robert L. , Fujiwara, Keiichi, Higgins, Kristin Ann , Jagsi, Reshma , Wolmark, Norman

Mayo Clinic

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: GS02-07-GS02-07

10.1158/1538-7445.sabcs23-gs02-07 Get It

Abstract Background: The benefit of adjuvant regional nodal irradiation including the chest wall after mastectomy (CWI+RNI) and with whole breast irradiation (WBI+RNI) after breast conserving surgery (BCS) is well established in pts with pathologically positive axillary nodes (pN+). Pts who present with axillary node involvement (cN+), receive neoadjuvant chemotherapy (NC), and are found to be pathologically node-negative at surgery (ypN0), have lower loco-regional recurrence (LRR) rates compared to those who remain pathologically node-positive (ypN+). This phase III, randomized trial aimed to evaluate whether CWI+RNI after mastectomy or addition of RNI to WBI after BCS significantly improves invasive breast cancer recurrence-free interval (IBC-RFI) in cN+ pts found to be ypN0 after NC. Methods: Eligible pts had clinical cT1-3, N1, M0 invasive breast cancer (biopsy-proven N+ by FNA/core needle bx), completed ≥8 wks of NC (and anti-HER2 therapy if HER2+), and were ypN0 after mastectomy or BCS and sentinel node biopsy (SLNB, ≥2 nodes), axillary lymph node dissection (ALND), or both. Pts were randomized to “No RNI” (i.e., observation after mastectomy or WBI after BCS) vs. “RNI” (i.e., CWI+RNI after mastectomy or WBI+RNI after BCS). Primary endpoint was IBC-RFI. Secondary endpoints reported here: LRR-free interval (LRRFI), distant recurrence-free interval (DRFI), disease-free survival (DFS), and overall survival (OS). Study was designed to have 80% power to detect 35% reduction in annual rate of IBC-RFI for an absolute risk reduction of 4.6% (5-yr cumulative rate). Per protocol, final analysis was to occur after 172 events or 10 yrs after study initiation.Here we report the time-driven analysis prespecified in the protocol. Results: From 9/13-12/20, 1,641 pts were enrolled; 1,556 pts were available for primary event analysis; median f/u time 59.5 mos (IQR 40.7-74.1). Pt/tumor characteristics were well balanced between groups. Median age 52 yrs (range 21-84); 31% non-white; 21% cT1, 60% cT2, 19% cT3; 23% triple-negative, 21% HR+/HER2-, 56% HER2+; 58% BCS; 55% SLNB, 45% ALND+/-SLNB; and 78% had breast pathologic complete response. At the time of the analysis, 109 IBC-RFI events (63% of the planned 172) were confirmed (“No RNI”: 59, “RNI”: 50). There was no statistically significant difference between groups for IBC-RFI (HR=0.88, 95%CI 0.60-1.29; p=0.51), 5-yr point estimates: 91.8% for “No RNI” and 92.7% for “RNI.” There were no statistically significant differences between the treatment groups for secondary endpoints. There were no study-related deaths and no unexpected toxicities.Grade 4 toxicity was rare (0.1% with “No RNI”, 0.5% with “RNI”); 6.5% of pts developed grade 3 toxicity in “No RNI” and 10% in “RNI” group. Most common grade 3 toxicity was radiation dermatitis (3.3% in “No RNI,” 5.7% in “RNI”). Conclusion: In pts who present with biopsy-proven axillary node involvement and convert their axillary nodes to ypN0 after NC, CWI+RNI after mastectomy, or WBI+RNI after BCS, did not significantly improve IBC-RFI, LRRFI, DRFI, DFS, or OS. These findings suggest that downstaging involved axillary nodes with NC can result in optimization of adjuvant radiotherapy without adversely affecting oncologic outcomes. Follow-up of pts for long-term outcomes continues. NCT01872975 *EPM and JW are co-first authors. Table 1 Citation Format: Eleftherios Mamounas, Hanna Bandos, Julia White, Thomas Julian, Atif Khan, Simona Shaitelman, Mylin Torres, Frank Vicini, Patricia Ganz, Susan McCloskey, Nilendu Gupta, X. Allen Li, Peter Lucas, Nadeem Abu-Rustum, Saumil Gandhi, Rahul Tendulkar, Robert Coleman, Keiichi Fujiwara, Samantha Seaward, William Irvin, Kristin Higgins, Robert Mutter, Jean-Francois Boileau, Andrew Muskovitz, Reshma Jagsi, Anna Weiss, Curran Walter Jr., Norman Wolmark. Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304 [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr GS02-07.
Exploring the Participant's Experience of Home-based Pulmonary Rehabilitation With Health Coaching After a COPD Related Hospitalization
Benzo, Roberto, Thomas, B.E., Benzo, M.V. , Barwise, Amelia

Mayo Clinic

D29. INSIGHTS INTO MECHANISMS AND EFFECTIVENESS OF DIFFERENT COMPONENTS OF PULMONARY REHABILITATION | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A7171-A7171

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7171 Get It

Grit and Resilience Among Pulmonary and Critical Care Medicine Physicians: A Multi-institutional Study
Hu, A.W., Beckman, Thomas J. , Chu, D.C., Patel, Harsh N. , Krutsinger, Dustin C. , Dhannoon, S., Keetley, Helen M, Kelm, Diana J. , Adamson, R., Denson, Joshua L. , LeMahieu, Allison

Mayo Clinic

D102. HOT TOPICS IN BEHAVIORAL SCIENCE AND HEALTH SERVICES RESEARCH | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A7307-A7307

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7307 Get It

Critical Hemodynamic Considerations for Adult Patients With Tetralogy of Fallot and Prior Blalock-Thomas-Taussig Shunt Surgery
García, Santiago , Kelm, D.

Mayo Clinic

A43. SHOCK AND AWE: NOVEL SHOCK CASES IN THE ICU | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1589-A1589

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1589 Get It

Increasing Adherence to Early Pulmonary Rehabilitation After COPD-related Hospitalization
Benzo, Roberto, Roy, M., Thomas, B.E., Hoult, Johanna, Midthun, William R., Clark, Mike , Benzo, M.V.

Mayo Clinic

A98. BEST INTERVENTION ABSTRACTS IN PULMONARY REHABILITATION | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A2759-A2759

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2759 Get It

Evaluation of Clinical Remission Indicators in Asthma Patients Treated With Biologics in a Real-world Setting
Corbridge, Thomas, Lee, L., Barman, Hannah , Manoharan, Mithun , Simsek, S., Wagner, Tyler , Deb, A., Lim, Kaiser G. , Wagner, T.

Mayo Clinic

A34. LATE BREAKING ABSTRACTS IN ASTHMA AND ALLERGIC INFLAMMATION | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1368-A1368

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1368 Get It

Alternative Pathway Complement Activation and Low Circulating Inhibitors Associate With Severity and Mortality in COVID-19 and Non-COVID Sepsis
Meyer, N.J., Devalaraja‐Narashimha, Kishor , Ehmann, Peter, Afolayan, Sunday, DerOhannessian, Stephanie, Spade, G., Ittner, C.A.G., Turner, A.P., Esperanza, Mika, Dunn, Thomas, Weaver, JoEllen , Biobank, P. PennMedicine, Zhu, Olivia, Scott, Daniel A. , Hamon, Sara , Wistermayer, A., Hersch, L., Burczynski, Michael E., Hamilton, Jennifer D. , Jones, T.K., Shashaty, M.G.S. , Reilly, J.P., Laudański, Krzysztof , Ko, Jina , Scott, D., Hooper, Andrea T. , Glass, David J. , Giannini, Heather M. , Morton, L., FitzGerald, Garret A , Rader, Daniel J

Mayo Clinic

A103. DYSREGULATED PATHWAYS IN SEPSIS AND LUNG INJURY: SEARCHING FOR TREATABLE TRAITS | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A2830-A2830

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2830 Get It